PIK3CA and follicular lymphoma: Copanlisib is an intravenously administered PI3K inhibitor typically used to treat relapsed and refractory follicular lymphoma, but the addition of copanlisib to trastuzumab and pertuzumab in HER2 + BC therapy could increase the duration of response as compared to the standard treatment, overcoming the resistance due to the hyperactivation of PI3K signaling downstream of HER2.